Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10490961

Modulating dendritic cells to optimize mucosal immunization protocols.

E Williamson·G M Westrich·J L Viney
View original source ↗Export metadata ↓

Abstract

Oral administration of soluble protein Ag induces tolerance, a phenomenon that has hampered mucosal vaccine design. To provoke active immunity, orally administered Ag must be fed together with a mucosal adjuvant such as cholera toxin (CT). Unfortunately, CT is not suitable for clinical use because of its associated toxicity. There is, therefore, a need to develop alternative mucosal immunization regimens. Here we have attempted to alter the intrinsically tolerogenic nature of the intestine and improve immunization potential by expanding and activating intestinal APC in vivo. Previous studies have indicated that intestinal dendritic cells (DC) present oral Ag, but do so in a tolerogenic manner. In the present study we investigated whether DC can be converted from tolerogenic into immunogenic APC by treating mice with Flt3 ligand (Flt3L), a DC growth factor, and then immunizing with CT. We observed increased local and systemic responses to CT in the presence of elevated numbers of intestinal DC. In parallel, CT induced up-regulation of CD80 and CD86 on these Flt3L-expanded DC. In an attempt to develop a toxin-free adjuvant system, we investigated whether IL-1 could be used as an alternative DC-activating stimulus. Using a combination of Flt3L and IL-1alpha, we observed a potent active response to fed soluble Ag, rather than the tolerogenic response normally observed. These data suggest that Flt3L-expanded DC are well positioned to regulate intestinal responses depending on the presence or the absence of inflammatory signals. Flt3L may therefore be a reagent useful for the design of mucosal immunization strategies.

Explore related subjects

Adjuvants, ImmunologicAdministration, OralAnimalsAntigen-Presenting CellsAntigensCD4-Positive T-LymphocytesCell DivisionCholera ToxinCytokinesDendritic CellsEpitopes, T-LymphocyteFemaleImmune ToleranceImmunity, InnateImmunity, MucosalImmunizationInflammation MediatorsInterleukin-1Intestinal MucosaLigandsMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicOvalbuminPeyer's PatchesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Williamson, G M Westrich, J L Viney. 1999-10-01. Modulating dendritic cells to optimize mucosal immunization protocols.. https://pubmed.ncbi.nlm.nih.gov/10490961/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome.

Liposome, although intensively researched as vaccine or drug delivery vehicle, has been of limited use due to the low and unpredictable long-term stability. In order to overcome such problems, polymerized liposome (PL) that could initiate polymerization under very mild reaction condition was examined and compared to a conventional liposome. The polymerizable lipid, 1,2-bis[12-(lipoyloxy)dodecanoyl]-sn-glycero-3-phosphorylcholine (DLL), was synthesized according to the literature, and 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) was used as the conventional lipid counterpart. Polymerization of liposome was as easy and convenient as just shaking in pH 7.4 buffer. The protein encapsulation efficiency of DLL was higher than that of DSPC, and its protein release rate was lower. Immunoglobulin G (IgG) activity examined after intraperitoneal injection of antigen encapsulated by either DLL or DSPC showed that ca. 2 times as much antibody was formed by DLL-encapsulated lysozyme compared with DSPC-encapsulated form. The reasons for the superior adjuvantic properties of DLL and its future application as a drug delivery system are briefly discussed.

Adjuvants, Immunologic↗
PubMed2002

BALB/c mice orally pretreated with diclofenac have augmented and accelerated PLNA responses to diclofenac.

The nonsteroidal anti-inflammatory drug (NSAID) diclofenac (DF) is associated with idiosyncratic hepatotoxicity and several other distinct hypersensitivity reactions. The mechanism(s) are unknown but evidence suggests both cell-mediated and antibody-mediated immune effector systems may be involved. In the present studies, the immunostimulating potential of DF was evaluated using the direct and TNP-Ficoll (trinitrophenyl (TNP)-Ficoll) popliteal lymph node assays (PLNA). These assays were conducted in naive mice, T-cell-deficient mice, or in mice that had been pretreated with a single oral dose of DF. In naive mice, DF induced a dose-, and time-dependent reaction in the direct PLNA. A significant increase in popliteal lymph node (PLN) weight and PLN cellularity was detected 7 days after the injection of 0.50 and 0.75 mg DF, whereas 0.25 mg DF produced no observable effect. With 0.75 mg, there was a rapid accumulation of cells in the PLN between days 5 and 6, with maximum PLN cellularity observed between days 7 and 10. The immunostimulating effects of DF were significantly attenuated in T-cell-deficient mice. In the TNP-Ficoll PLNA conducted in naive mice, DF caused a dose-dependent increase in PLN cellularity on day 7 with a time-dependent increase in anti-TNP antibody forming cells (AFCs) in the PLN; the reaction was dominated by IgM anti-TNP AFCs from day 4 through day 7, but IgG1 anti-TNP AFCs and IgG3 anti-TNP AFCs were detected beginning on day 5 and day 6, respectively. Relative to mice pretreated with vehicle (ddH2O), mice orally pretreated with DF had a significantly greater increase in PLN weight 5 days following the injection of 0.25 mg DF and a significantly greater increase in PLN weight and cellularity 4 days following the injection of 0.50 mg DF. Oral pretreatment with DF had no observable effect on the direct PLN reaction induced following the footpad injection of the irrelevant drugs, D-penicillamine (D-PEN) or streptozotocin. When 0.50 mg DF was co-injected with TNP-Ficoll, mice orally pretreated with DF, compared to vehicle-pretreated mice, and had a significantly greater increase in IgM anti-TNP AFCs on day 4, and a significant increase in both IgG1 and IgG3 anti-TNP AFCs on day 7. Additionally, IgG1 anti-TNP AFCs were detected in the PLN of DF-pretreated mice as early as day 4. No differences in anti-TNP AFCs were detected when orally pretreated mice were injected with 0.50 mg D-PEN. Collectively, these results demonstrated that DF (i) is an immunostimulating drug that induced a dose-, time- and T-cell-dependent PLN reaction in naive mice, (ii) provided non-cognate help that produced antibody against co-injected TNP-Ficoll, and (iii) mice orally pretreated with DF had DF-specific increased responsiveness in the direct PLNA, which (iv) resulted in accelerated and augmented AFC production against co-injected TNP-Ficoll. These novel findings suggest that oral administration of DF may result in primed T cells that respond with footpad injection. Thus, the oral pretreatment modification of the PLNA should be further explored as a possible alternative to hypersensitivity testing with drugs administered via the oral route. Additional studies with other compounds known to produce hypersensitivity reactions are needed.

Adjuvants, Immunologic↗